NCT02132429View on ClinicalTrials.gov

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Migraine
Interventions
DRUG

AMG 333

Oral administration available in varying dose strength.

DRUG

Placebo

Placebo containing no active drug

Trial Locations (1)

84106

CRI Lifetree, Salt Lake City

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY